BCRX - BioCryst Pharmaceuticals Inc Stock Price, Fair Value and News

4.22USD+0.06 (+1.44%)Delayed as of 26 Apr 2024, 10:05 am ET

Market Summary

USD4.22+0.06

Delayedas of 26 Apr 2024, 10:05 am

1.44%

BCRX Stock Price

View Fullscreen

BCRX RSI Chart

BCRX Valuation

Market Cap

857.6M

Price/Earnings (Trailing)

-3.79

Price/Sales (Trailing)

2.59

EV/EBITDA

-9.03

Price/Free Cashflow

-9.01

BCRX Price/Sales (Trailing)

BCRX Profitability

EBT Margin

-68.26%

Return on Equity

-18.79%

Return on Assets

-43.82%

Free Cashflow Yield

-11.09%

BCRX Fundamentals

BCRX Revenue

Revenue (TTM)

331.4M

Rev. Growth (Yr)

17.42%

Rev. Growth (Qtr)

7.68%

BCRX Earnings

Earnings (TTM)

-226.5M

Earnings Growth (Yr)

13.71%

Earnings Growth (Qtr)

-70.77%

Breaking Down BCRX Revenue

52 Week Range

4.129.07

(Low)(High)

Last 7 days

-7.6%

Last 30 days

-17.0%

Last 90 days

-23.5%

Trailing 12 Months

-45.4%

How does BCRX drawdown profile look like?

BCRX Financial Health

Current Ratio

3.31

Debt/Equity

0.25

Debt/Cashflow

-0.31

BCRX Investor Care

Shares Dilution (1Y)

9.39%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	289.7M	306.6M	317.6M	331.4M
2022	188.0M	203.6M	238.4M	270.8M
2021	32.0M	79.1M	114.0M	157.2M
2020	47.8M	49.2M	53.5M	17.8M
2019	22.6M	11.5M	11.8M	48.8M
2018	19.7M	29.1M	21.8M	20.7M
2017	31.0M	29.3M	30.3M	25.2M
2016	46.3M	25.2M	22.0M	26.4M
2015	17.0M	41.4M	49.1M	48.3M
2014	17.2M	17.9M	18.7M	13.6M
2013	16.2M	12.8M	12.3M	17.3M
2012	26.4M	26.9M	24.5M	24.8M
2011	41.7M	37.9M	31.1M	19.6M
2010	0	70.5M	66.5M	62.4M
2009	0	0	0	74.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of BioCryst Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	thackray helen m.	sold (taxes)	-38,227	5.08	-7,525	chief r&d officer
Feb 29, 2024	milano vincent	acquired	5,624	5.63	999	-
Feb 29, 2024	heggie theresa	acquired	5,624	5.63	999	-
Jan 03, 2024	stonehouse jon p	gifted	-	-	-20,000	president & ceo
Jan 03, 2024	stonehouse jon p	gifted	-	-	10,000	president & ceo
Dec 19, 2023	barnes alane p	sold (taxes)	-15,016	6.05	-2,482	chief legal officer
Dec 19, 2023	stonehouse jon p	sold (taxes)	-85,238	6.05	-14,089	president & ceo
Dec 19, 2023	gayer charles k	sold (taxes)	-15,016	6.05	-2,482	chief commercial officer
Dec 19, 2023	thackray helen m.	sold (taxes)	-33,759	6.05	-5,580	chief r&d officer

Which funds bought or sold BCRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-79,000	375,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-26.92	-1,205,840	1,965,380	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	new	-	76.00	76.00	-%
Apr 24, 2024	AlphaCentric Advisors LLC	unchanged	-	-614,250	3,429,000	2.07%
Apr 23, 2024	BENDER ROBERT & ASSOCIATES	sold off	-100	-339,034	-	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	reduced	-2.08	-2,231,740	10,929,800	0.62%
Apr 23, 2024	AMALGAMATED BANK	reduced	-73.83	-113,000	32,000	-%
Apr 23, 2024	FIFTH THIRD BANCORP	sold off	-100	-20,965	-	-%
Apr 22, 2024	Oakworth Capital, Inc.	unchanged	-	-928	5,182	-%
Apr 22, 2024	Stonegate Investment Group, LLC	added	1.22	-41,531	251,907	0.01%

Are Funds Buying or Selling BCRX?

Are funds buying BCRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCRX

No. of Funds

Unveiling BioCryst Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	avoro capital advisors llc	6.4%	13,050,000	SC 13G
Feb 14, 2024	baker bros. advisors lp	4.94%	10,126,176	SC 13G/A
Feb 13, 2024	vanguard group inc	8.67%	17,763,720	SC 13G/A
Jan 24, 2024	state street corp	6.24%	12,777,003	SC 13G/A
Jan 24, 2024	blackrock inc.	9.1%	18,681,370	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.91%	19,106,881	SC 13G/A
Feb 09, 2023	vanguard group inc	7.62%	14,204,395	SC 13G/A
Feb 06, 2023	state street corp	5.97%	11,126,861	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	14,918,955	SC 13G/A
Feb 14, 2022	baker bros. advisors lp	9.91%	18,386,831	SC 13G/A

Recent SEC filings of BioCryst Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Feb 27, 2024	S-3ASR	S-3ASR
Feb 27, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to BioCryst Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

BioCryst Pharmaceuticals Inc News

Latest updates

BioCryst Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.7%	93,401,000	86,742,000	82,491,000	68,778,000	79,545,000	75,827,000	65,532,000	49,923,000	47,158,000	40,994,000	49,959,000	19,059,000	4,016,000	6,102,000	2,871,000	4,823,000	39,725,000	1,775,000	1,448,000	5,887,000	2,729,000
Costs and Expenses	37.9%	136,071,000	98,663,000	103,194,000	97,193,000	125,856,000	93,272,000	100,254,000	99,880,000	99,335,000	85,578,000	79,541,000	70,436,000	56,421,000	48,966,000	41,381,000	45,801,000	39,834,000	36,873,000	36,366,000	35,217,000	27,991,000
S&GA Expenses	27.1%	64,382,000	50,648,000	50,997,000	47,867,000	50,153,000	36,919,000	38,017,000	34,282,000	35,387,000	34,992,000	26,325,000	22,114,000	20,986,000	17,195,000	13,883,000	15,865,000	10,489,000	11,735,000	8,659,000	6,238,000	4,490,000
R&D Expenses	49.4%	70,052,000	46,879,000	51,247,000	48,388,000	73,207,000	52,740,000	61,990,000	65,360,000	63,529,000	49,971,000	52,873,000	42,435,000	35,354,000	30,245,000	27,498,000	29,867,000	26,774,000	25,120,000	27,681,000	27,493,000	23,431,000
EBITDA Margin	9.2%	-0.35	-0.39	-0.43	-0.41	-0.53	-0.40	-0.61	-0.64	-0.77	-1.19	-1.86	-4.92	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.1%	24,583,000	27,345,000	28,915,000	27,396,000	26,458,000	24,775,000	24,022,000	23,837,000	18,780,000	14,115,000	13,495,000	12,904,000	5,609,000	2,927,000	2,918,000	3,047,000	3,087,000	3,044,000	3,035,000	2,726,000	2,414,000
Income Taxes	-533.6%	-1,431,000	330,000	740,000	671,000	76,000	1,522,000	856,000	279,000	2,253,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-76.3%	-63,162,000	-35,819,000	-74,586,000	-52,662,000	-71,465,000	-40,998,000	-58,003,000	-73,917,000	-15,526,000	-58,801,000	-43,198,000	-64,284,000	-	-	-	-	-	-	-	-	-
EBT Margin	7.6%	-0.68	-0.74	-0.78	-0.77	-0.90	-0.79	-1.01	-1.02	-1.16	-1.60	-2.31	-5.70	-	-	-	-	-	-	-	-	-
Net Income	-70.8%	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000	-17,779,000	-58,801,000	-43,198,000	-64,284,000	-60,493,000	-46,115,000	-38,607,000	-37,599,000	-2,622,000	-37,592,000	-37,629,000	-31,054,000	-27,432,000
Net Income Margin	8.2%	-0.68	-0.74	-0.79	-0.78	-0.91	-0.81	-1.03	-1.03	-1.17	-1.99	-2.71	-6.54	-	-	-	-	-	-	-	-	-
Free Cashflow	55.2%	-8,918,000	-19,897,000	-18,814,000	-47,512,000	-23,849,000	-32,444,000	-27,757,000	-77,800,000	-32,459,000	-23,276,000	-25,411,000	-61,011,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.1%	517	523	530	510	550	559	511	528	588	266	277	284	335	176	215	137	175	91.00	116	142	147
Current Assets	-1.3%	496	502	511	491	517	509	495	512	566	253	266	274	324	162	204	126	164	79.00	104	118	114
Cash Equivalents	-26.7%	111	151	146	155	305	247	273	396	504	200	210	227	272	96.00	173	102	114	30.00	31.00	35.00	27.00
Inventory	-3.2%	29.00	30.00	27.00	27.00	28.00	27.00	23.00	16.00	16.00	14.00	10.00	5.00	7.00	6.00	5.00	-	-	2.00	1.00	1.00	2.00
Net PPE	-12.1%	8.00	9.00	8.00	8.00	9.00	8.00	9.00	9.00	9.00	8.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	8.00	8.00	9.00
Current Liabilities	65.3%	150	91.00	93.00	85.00	106	82.00	95.00	81.00	104	134	116	101	106	112	103	93.00	92.00	82.00	72.00	66.00	69.00
Long Term Debt	1.8%	303	298	293	233	232	224	145	140	136	132	127	123	120	-	-	-	-	-	-	-	-
LT Debt, Non Current	1.8%	303	298	293	233	232	224	145	140	136	132	127	123	120	-	-	-	-	-	-	-	-
Shareholder's Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.00	77.00	4.00	38.00	-	-	23.00	49.00
Retained Earnings	-3.8%	-1,681	-1,619	-1,583	-1,507	-1,454	-1,383	-1,340	-1,281	-1,207	-1,189	-1,130	-1,087	-1,023	-962	-916	-878	-840	-838	-800	-762	-731
Additional Paid-In Capital	1.4%	1,222	1,206	1,192	1,177	1,158	1,139	1,125	1,115	1,098	1,041	1,023	1,011	1,002	995	992	880	877	796	790	784	780
Shares Outstanding	8.4%	206	190	189	189	188	186	185	185	179	178	178	178	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,323	-	1,949	-	-	-	-	-	2,801	-	-	-	833	-	-	-	414	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	55.2%	-8,918	-19,897	-18,814	-47,512	-23,849	-32,444	-27,757	-77,800	-32,459	-23,276	-25,411	-61,011	-42,531	-38,255	-31,041	-23,281	-10,448	-27,637	-24,501	-26,998	-23,985
Share Based Compensation	34.3%	16,488	12,279	12,841	14,007	15,282	9,951	9,867	9,601	8,500	13,029	7,632	5,479	5,887	2,873	3,280	2,754	3,688	5,329	5,385	3,317	2,324
Cashflow From Investing	-223.2%	-28,473	23,119	-19,035	-107,109	77,215	-69,543	-97,438	-38,472	-11,120	7,747	4,504	14,673	21,414	-34,062	-4,932	10,724	16,261	23,514	22,278	15,881	-3,167
Cashflow From Financing	-359.0%	-3,173	1,225	29,356	5,077	4,199	76,325	147	7,356	347,418	4,776	4,574	2,900	196,760	-4,634	108,197	266	78,460	184	414	20,040	1,337

BCRX Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues [Abstract]
Revenues	$ 331,412	$ 270,827	$ 157,170
Expenses:
Cost of product sales	4,481	6,408	7,229
Research and development	216,566	253,297	208,808
Selling, general and administrative	213,894	159,371	118,818
Royalty	180	186	35
Total operating expenses	435,121	419,262	334,890
Loss from operations	(103,709)	(148,435)	(177,720)
Interest and other income	15,777	5,127	62
Interest expense	(108,239)	(99,092)	(59,294)
(Loss) gain on extinguishment of debt	(29,019)	0	55,838
Foreign currency losses, net	(1,039)	(1,983)	(695)
Loss before income taxes	(226,229)	(244,383)	(181,809)
Income tax expense	310	2,733	2,253
Net loss	(226,539)	(247,116)	(184,062)
Foreign currency translation adjustment	180	890	189
Unrealized gain (loss) on available for sale investments	1,131	(1,041)	(15)
Net comprehensive loss	$ (225,228)	$ (247,267)	$ (183,888)
Earnings per share, basic (in usd per share)	$ (1.18)	$ (1.33)	$ (1.03)
Earnings per share, diluted (in usd per share)	$ (1.18)	$ (1.33)	$ (1.03)
Weighted average shares outstanding, basic (in shares)	192,198	185,908	179,117
Weighted average shares outstanding, diluted (in shares)	192,198	185,908	179,117

BCRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 110,643	$ 304,767
Restricted cash	1,804	1,472
Investments	278,344	119,543
Trade receivables	56,950	50,599
Inventory, net	28,683	27,533
Prepaid expenses and other current assets	19,542	12,586
Total current assets	495,966	516,500
Property and equipment, net	7,910	8,617
Long-term investments	0	18,077
Other assets	13,084	6,806
Total assets	516,960	550,000
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	20,893	14,356
Accrued expenses	102,882	87,565
Deferred revenue	0	1,224
Operating lease liabilities	1,058	1,516
Finance lease liabilities	1,590	853
Royalty financing obligations	23,565	0
Total current liabilities	149,988	105,514
Operating lease liabilities	8,390	4,027
Finance lease liabilities	2,845	1,777
Royalty financing obligations	508,034	501,655
Secured term loan	303,231	231,624
Stockholders’ deficit:
Preferred stock, $0.01 par value; shares authorized — 5,000; no shares outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.01 par value; shares authorized — 450,000; shares issued and outstanding – 205,771 and 187,906 at December 31, 2023 and 2022, respectively	2,058	1,879
Additional paid-in capital	1,222,236	1,158,118
Accumulated other comprehensive income	1,337	26
Accumulated deficit	(1,681,159)	(1,454,620)
Total stockholders’ deficit	(455,528)	(294,597)
Total liabilities and stockholders’ deficit	$ 516,960	$ 550,000

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

CEO	Mr. Jon P. Stonehouse
WEBSITE	biocryst.com
INDUSTRY	Biotechnology
EMPLOYEES	531

BioCryst Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for BioCryst Pharmaceuticals Inc? What does BCRX stand for in stocks?

BCRX is the stock ticker symbol of BioCryst Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioCryst Pharmaceuticals Inc (BCRX)?

As of Thu Apr 25 2024, market cap of BioCryst Pharmaceuticals Inc is 857.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCRX stock?

You can check BCRX's fair value in chart for subscribers.

What is the fair value of BCRX stock?

You can check BCRX's fair value in chart for subscribers. The fair value of BioCryst Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioCryst Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioCryst Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether BCRX is over valued or under valued. Whether BioCryst Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact BioCryst Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCRX.

What is BioCryst Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, BCRX's PE ratio (Price to Earnings) is -3.79 and Price to Sales (PS) ratio is 2.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioCryst Pharmaceuticals Inc's stock?

In the past 10 years, BioCryst Pharmaceuticals Inc has provided -0.06 (multiply by 100 for percentage) rate of return.